Public Equities, L.P.Invus ... Net Worth

The estimated Net Worth of Public Equities, L.P.Invus ... is at least 1.5 百万$ dollars as of 7 August 2024. Public Invus owns over 322,361 units of GlycoMimetics Inc stock worth over 1,010,810$ and over the last few years Public sold GLYC stock worth over 490,247$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Public Invus GLYC stock SEC Form 4 insiders trading

Public has made over 4 trades of the GlycoMimetics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Public sold 322,361 units of GLYC stock worth 61,249$ on 7 August 2024.

The largest trade Public's ever made was selling 1,379,119 units of GlycoMimetics Inc stock on 26 July 2024 worth over 317,197$. On average, Public trades about 567,875 units every 3 days since 2024. As of 7 August 2024 Public still owns at least 6,317,565 units of GlycoMimetics Inc stock.

You can see the complete history of Public Invus stock trades at the bottom of the page.

Insiders trading at GlycoMimetics Inc

Over the last 11 years, insiders at GlycoMimetics Inc have traded over 15,299,593$ worth of GlycoMimetics Inc stock and bought 10,868,557 units worth 48,421,008$ . The most active insiders traders include Scott D Sandell、Peter J Barris、M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of 38,210$. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth 61,249$.

What does GlycoMimetics Inc do?

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.

Complete history of Public Invus stock trades at GlycoMimetics Inc

GlycoMimetics Inc executives and stock owners

GlycoMimetics Inc executives and other stock owners filed with the SEC include:

• Rachel King,
  President, Chief Executive Officer, Co-Founder, Director
• Brian Hahn,
  Chief Financial Officer
• Helen Thackray,
  Senior Vice President - Clinical Development, Chief Medical Officer
• John Magnani,
  Co-Founder, Senior Vice President, Chief Scientific Officer
• Rachel K. King,
  Pres, CEO & Director
• Brian M. Hahn,
  Sr. VP & CFO
• Timothy Pearson,
  Independent Chairman of the Board
• Daniel Junius,
  Independent Director
• Mark Goldberg,
  Independent Director
• Scott Jackson,
  Independent Director
• Patricia Andrews,
  Independent Director
• Scott Koenig,
  Independent Director
• Armand Girard,
  Senior Vice President, Chief Business Officer
• Bruce Johnson,
  Sr. VP & Chief Commercial Officer
• Armand Girard,
  Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.
• Dr. John L. Magnani,
  Sr. VP of Research & Chief Scientific Officer
• Harout Semerjian,
  CEO, Pres & Director
• Dr. Eric J. Feldman M.D.,
  Sr. VP & Chief Medical Officer
• Christian Dinneen-Long,
  VP, Corp. Counsel & Corp. Sec.
• Henry Flanner,
  VP of Technical Operations
• Stephanie R. Irish,
  VP of Accounting
• Partners L P/Ilbiotechnolog...,
  
• Scott D Sandell,
  10% owner
• Franklin H Jr Top,
  Director
• Peter J Barris,
  10% owner
• Michael A Henos,
  Director
• M James Barrett,
  Director
• Enterprise Associates 10 L ...,
  
• John J. Baldwin,
  Director
• Chinmaya Rath,
  SVP and Chief Business Officer
• William M. Gust,
  Director
• Enterprise Associates 13 Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• Harout Semerjian,
  Chief Executive Officer
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Invus ...,
  
• Bruce S Johnson,
  SVP & Chief Commercial Officer
• Edwin Rock,
  Chief Medical Officer